Results 161 to 170 of about 12,338 (219)
The Dual Role of Autophagy in Cancer: Mechanisms and Therapeutic Strategies
MedComm – Oncology, Volume 5, Issue 2, June 2026.Autophagy is a conserved cellular process degrading dysfunctional organelles and protein aggregates to maintain cell homeostasis, and it exhibits context‐dependent duality in cancer. Autophagy functions as a critical tumor‐suppressive mechanism by preventing DNA damage and mutation during tumor initiation.
Xiang‐Zheng Gao +4 more
wiley +1 more source
Muscle &Nerve, Volume 73, Issue 6, Page 942-951, June 2026.ABSTRACT This review examines the emerging application of chimeric antigen receptor (CAR) T‐cell therapy in myasthenia gravis (MG), with emphasis on safety, efficacy signals, and future therapeutic potential in treatment‐refractory disease. A comprehensive literature search was conducted across PubMed, medRxiv, bioRxiv, and Google Scholar for studies ...
Tobias Hegelmaier +7 more
wiley +1 more source
A Case Report of a Special Type of Multiple Myeloma: Kappa Light Chain‐Only
Organ Medicine, Volume 3, Issue 2, Page 119-124, June 2026.This case illustrates the clinical course of a patient diagnosed with kappa light chain‐only multiple myeloma, a rare subtype of multiple myeloma. Of note, light chain multiple myeloma is characterized by rapid disease progression and severe target organ damage.
Yanhua Dai +8 more
wiley +1 more source
CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 6, June 2026.ABSTRACT Quantitative modeling can guide drug development and regulatory decisions by providing insights into pharmacokinetics, pharmacodynamics, efficacy, and safety. Integrating models allows simulations that support dosing considerations. A simulation framework for belantamab mafodotin (B) in relapsed/refractory multiple myeloma was developed using ...
Fernando Carreño +8 more
wiley +1 more source
British Journal of Haematology, Volume 208, Issue 6, Page 2059-2068, June 2026.Renal dysfunction represents a possible underrecognized complication of symptomatic WM; this condition correlates with adverse global and disease‐specific clinical outcomes. Summary The prognostic significance of impaired renal function in Waldenström macroglobulinaemia (WM) remains poorly defined.
Nicolò Danesin +27 more
wiley +1 more source
British Journal of Haematology, Volume 208, Issue 6, Page 2096-2103, June 2026.Summary Anti‐CD38 monoclonal antibodies dramatically improve the prognosis in immunoglobulin light‐chain (AL) amyloidosis, yet patients with end‐stage (Mayo 2004 IIIB) disease are typically excluded from prospective trials. To evaluate the daratumumab plus bortezomib and dexamethasone (Dara‐VD) regimen in Mayo 2004 stage III patients, we conducted a ...
Gao Xue‐min +7 more
wiley +1 more source
British Journal of Haematology, Volume 208, Issue 6, Page 2069-2078, June 2026.In newly diagnosed multiple myeloma patients in ≥Very Good Partial Remission (VGPR) after a first‐line therapy daratumumab as consolidation/maintenance improved long‐term minimal residual disease negativity. Summary Daratumumab is approved for front‐line and relapsed myeloma therapy.
Alessandro Gozzetti +24 more
wiley +1 more source
Biochemical bone biomarkers in plasma cell dyscrasias
British Journal of Haematology, Volume 208, Issue 6, Page 1909-1923, June 2026.Visual abstract depicting that bone turnover markers reflect dynamic alterations in bone remodelling across the spectrum of plasma cell dyscrasias but remain limited by assay variability, biological confounding and incomplete integration with imaging and risk stratification.
Guido Nador +4 more
wiley +1 more source
British Journal of Haematology, Volume 208, Issue 6, Page 2260-2264, June 2026.A subgroup analysis of efficacy, safety and QOL in patients who received selinexor in combination with bortezomib and dexamethasone (SVd) with and without selinexor dose reduction and who had lenalidomide‐refractory disease in the phase 3 BOSTON trial showed improvements in efficacy, quality of life (QOL) and safety outcomes with selinexor dose ...
Sosana Delimpasi +8 more
wiley +1 more source